Skip to main content

William B. Tabayoyong, M.D., Ph.D.

Contact Information

Phone Numbers

Appointment: (585) 275-2838

Fax: (585) 273-1068

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Surgery, Urology


Dr. Tabayoyong is a Urologic Oncologist who specializes in both minimally invasive urologic oncology (robotic surgery of the bladder, prostate, and kidney cancers) and advanced open pelvic and retroperitoneal cancer surgery. Dr. Tabayoyong has clinical expertise in all aspects of general urology with special emphasis on the following: Bladder Cancer, Prostate Cancer, Kidney Cancer, Testicular Cancer, Penile Cancer.

Dr. Tabayoyong received his medical degree and PhD in Immunology at the University of Iowa’s Carver College of Medicine Medical Scientist Training Program at the University of Iowa in Iowa City, Iowa in 2011. He completed his urology residency at Case Western Reserve University School of Medicine in Cleveland, Ohio, in 2017. Following residency, he completed a two-year Society of Urologic Oncology fellowship at the University of Texas, MD Anderson Cancer Center in Houston, Texas, in 2019. His research interest is in Immunotherapy for urologic cancers, with primary focus on bladder cancer.




    MD | University Of Iowa Roy J & Lucille A Carver College Of Medicine

    Post-doctoral Training & Residency

    07/01/2017 - 06/30/2019
    Fellowship in Urologic Oncology at University of Texas MD Anderson Cancer Center

    07/01/2012 - 06/30/2017
    Residency in Urology at University Hospitals Cleveland Medical Center

    07/01/2011 - 06/30/2012
    Internship in Surgery (General Surgery) at University Hospitals Cleveland Medical Center

    VIEW ALL expand_more

    Clinical Trials

    A Phase 1a/b Dose Finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

    Lead Researcher: William B Tabayoyong

    This study is open-label dose expansion study to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of bladder tumor (TURBT) and/or biopsy using TARA-002 in adults unable to obtain intravesical Bacillus Calmette-Guérin (BCG), adults who have received at least one dose of intravesical BCG or adults who have received at least one dose of intravesical chemotherapy. After completion of the dose escalation phase (Phase 1a) and after the RP2D has been established, the dose expansion phase (Phase 1b) will start enrollment of subjects with CIS NMIBC with active disease to further evaluate the safety and preliminary efficacy of TARA-002, at the established RP2D. CIS NMIBC with active disease is defined as disease present at the last cystoscopic evaluation prior to signing the ICF. Subjects enrolled in the dose expansion phase will not include subjects previously enrolled and treated in the dose escalation phase. All subjects will receive 6 weeks of treatment at the established RP2D.

    View Study Details


    Journal Articles

    Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. "Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members." Urologic oncology.. 2020 May 16; Epub 2020 May 16.

    Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. "Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign." European urology oncology.. 2019 May; 2(3):286-293. Epub 2018 Sep 10.

    Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. "Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease." European urology.. 2019 Jan; 75(1):8-10. Epub 2018 Oct 06.

    Books & Chapters

    Chapter Title: Radical Prostatectomy
    Book Title: Netter's Surgical Anatomy and Approaches
    Author List: Conor P. Delaney
    Published By: Elsevier 2014 in Philadelphia, PA




    William Tabayoyong, MD, UR Medicine Urology


    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.